43 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of Potent and Selective Inhibitors of Cdc2-Like Kinase 1 (CLK1) as a New Class of Autophagy Inducers.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Sichuan University and Collaborative Innovation Center For Biotherapy
Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Qimr Berghofer Medical Research Institute
Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Saarland University
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Icahn School of Medicine At Mount Sinai
Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Angelini
Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
India Academy of Scientific & Innovative Research (Acsir)
10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Technische Universit£T Braunschweig
Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Institut De Chimie Des Substances Naturelles
Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Exelixis
Novel Inverse Binding Mode of Indirubin Derivatives Yields Improved Selectivity for DYRK Kinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Athens
Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Cnrs
Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Harvard Medical School
1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
RhôNe-Poulenc Rorer
Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universite£? De Rennes 1
Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
National Human Genome Research Institute
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ambit Biosciences
Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/?-synuclein aggregation inhibitors with neuroprotective effects.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
German University In Cairo
Structure-Activity Relationship in the Leucettine Family of Kinase Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Manros Therapeutics & Perha Pharmaceuticals
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Louisiana At Lafayette
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Servier Research Institute of Medicinal Chemistry
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Vernalis (R&D)
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Sussex
Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Masaryk University
DFG-1 Residue Controls Inhibitor Binding Mode and Affinity, Providing a Basis for Rational Design of Kinase Inhibitor Selectivity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Goethe-University Frankfurt
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Beijing Normal University
An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Oxford
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Vertex Pharmaceuticals (Europe)
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Florida
A ?-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Universit£
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Seoul National University
ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Vertex Pharmaceuticals